PERSPECTA

News from every angle

← Back to headlines

Novo Nordisk Raises Outlook on Strong Wegovy Sales

Novo Nordisk reported mixed first-quarter results but significantly raised its financial outlook for fiscal year 2026. This optimistic forecast is primarily driven by the strong sales performance of its Wegovy pill, intensifying competition in the GLP-1 drug market.

6 May, 06:11 — 6 May, 06:11
PostShare

Sources

Showing 1 of 3 sources
seeking-alphaMixed1h ago

Novo Nordisk reports mixed Q1 results; raises FY26 outlook

Read full article →

Coverage Timeline

First report: seeking-alpha · 6 May, 06:11Full coverage: 3 · 43mWindow: 43m
Left-leaningCenterRight-leaning
seeking-alpha6 May, 06:11First to report

Novo Nordisk reports mixed Q1 results; raises FY26 outlook

politiken6 May, 06:12

Novo Nordisk hæver forventninger efter lancering af Wegovy-pille

naftemporiki6 May, 06:54Latest update

Novo Nordisk: Το χάπι του Wegovy απογειώνει τις πωλήσεις – Η νέα μάχη των GLP-1 αλλάζει τη φαρμακοβιομηχανία

Related Stories

Tacloban logs 45°C heat index, DOH warns of heat stroke risks

just now

Bulgarian Initiative Repurposes Vape Batteries to Power Park Lighting

15m ago

Iran Shopping Center Fire Kills 8, Injures 40 Near Tehran

16m ago

Deadly Fire at Iran Shopping Center Kills Eight

16m ago